Ultragenyx Pharmaceutical (RARE) Shares Outstanding (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Shares Outstanding (Entity) for 14 consecutive years, with $98.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 4.68% year-over-year to $98.3 million; the TTM figure through Mar 2026 stood at $98.3 million (up 4.68% YoY), while the FY2025 annual figure was $96.6 million, up 4.45% from the prior year.
• Shares Outstanding (Entity) climbed to $98.3 million in Q1 2026 per RARE's latest filing, from $96.6 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $98.3 million in Q1 2026 and bottomed at $69.8 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $83.4 million across 5 years, with a median of $83.1 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) climbed 1.23% — and 2024, when it climbed 28.92%.
• Ultragenyx Pharmaceutical's Shares Outstanding (Entity) stood at $70.2 million in 2022, then climbed by 17.26% to $82.3 million in 2023, then climbed by 12.35% to $92.5 million in 2024, then grew by 4.45% to $96.6 million in 2025, then climbed by 1.76% to $98.3 million in 2026.
• Business Quant data shows RARE's Shares Outstanding (Entity) at $98.3 million in Q1 2026, $96.6 million in Q4 2025, and $96.4 million in Q3 2025.